title: [Captopril in hypertensive patients with type II diabetes mellitus].
abstract: Since the angiotensin converting enzyme (ACE) is identical with kininase II, the reduction of its activity by an ACE-inhibitor such as captopril will not only decrease the concentration of angiotensin II but also elevate the levels of kinins. Although the slight increase of the latter will not contribute to the antihypertensive action of ACE-inhibitors, we are sure today that it exhibits local metabolic effects in cardiac and skeletal muscle tissue. These endogenous kinins have been shown to improve the utilisation of glucose in the human forearm, the whole organism and the isolated perfused rat heart and seem to exhibit their effects via prostaglandins. A cross-over plot of the glycolytic intermediates at the height of phosphofructokinase induced by bradykinin in rat heart and the activation of the purified enzyme from rabbit heart by PGE2 point to an enhanced glycolytic rate as their mode of action. From these findings similar effects under ACE-inhibitors can be assumed. This was investigated in ten non-insulin-dependent diabetics, whose glucose disposal rate was measured by the glucose clamp technique. After 25 mg of captopril their peripheral insulin resistance was significantly improved, which was found to be due to an accelerated rate of glucose uptake into their forearm muscle tissue. To evaluate the clinical relevance of these data, 15 mildly hypertensive, overweight type II-diabetic patients (mean age: 53 years; seven women) were hospitalized. After a seven-day wash-out period, the patients were given 25 mg of captopril twice daily for seven days. During the treatment, systemic kinin concentrations significantly increased.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: I. Medizinische Klinik Rotkreuzkrankenhaus, München.
authors.forename: G J
authors.initials: GJ
authors.lastname: Dietze
authors.forename: K
authors.initials: K
authors.lastname: Rett
authors.forename: K W
authors.initials: KW
authors.lastname: Jauch
authors.forename: M
authors.initials: M
authors.lastname: Wicklmayr
authors.forename: E
authors.initials: E
authors.lastname: Fink
authors.forename: W
authors.initials: W
authors.lastname: Hartl
authors.forename: B
authors.initials: B
authors.lastname: Günther
authors.forename: H
authors.initials: H
authors.lastname: Fritz
authors.forename: H
authors.initials: H
authors.lastname: Mehnert
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D002216:Captopril / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D001786:Blood Glucose; D002216:Captopril; D006442:Glycated Hemoglobin
vernacular_title: Captopril bei Hypertonikern mit Diabetes mellitus Typ II.